Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Receivables (2022 - 2025)

Corvus Pharmaceuticals has reported Change in Receivables over the past 4 years, most recently at $5000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at $5000.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was -$38000.0 (down 157.58% YoY), and the annual figure for FY2025 was -$38000.0, down 177.55%.
  • Change in Receivables for Q4 2025 was $5000.0 at Corvus Pharmaceuticals, up from -$54000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for CRVS hit a ceiling of $130000.0 in Q3 2022 and a floor of -$429000.0 in Q2 2023.
  • Median Change in Receivables over the past 4 years was $5000.0 (2024), compared with a mean of -$36846.2.
  • Biggest five-year swings in Change in Receivables: surged 218.18% in 2024 and later tumbled 254.29% in 2025.
  • Corvus Pharmaceuticals' Change in Receivables stood at $85000.0 in 2022, then tumbled by 82.35% to $15000.0 in 2023, then crashed by 66.67% to $5000.0 in 2024, then changed by 0.0% to $5000.0 in 2025.
  • The last three reported values for Change in Receivables were $5000.0 (Q4 2025), -$54000.0 (Q3 2025), and $7000.0 (Q2 2025) per Business Quant data.